Patent · US Active

Indazolones as modulators of TNF signaling

US9879016B2 · kind B2 · utility

2Cited by
0References
26Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 15, 2016
Grant dateJan 30, 2018
Priority date—
Expiry dateApr 15, 2036

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D519/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The disclosure provides compounds of Formula (I)pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.